Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an announcement.
Prescient Therapeutics has successfully resolved technical challenges in its OmniCAR program, a next-generation CAR-cell platform designed to improve cellular immunotherapy. The new OmniCAR variants have shown improved safety and effective tumor-killing activity in pre-clinical studies, allowing the program to progress further. This advancement positions Prescient to continue its innovative work in cancer treatment, potentially enhancing its standing in the oncology field and offering promising options for stakeholders involved in cell therapy development.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer treatment, including targeted and cellular therapies. Its targeted therapy, PTX-100, is a first-in-class compound aimed at blocking a key cancer growth enzyme and is currently in clinical trials for T-cell lymphomas. The company also has cell therapy platforms such as CellPryme-M and CellPryme-A, which enhance the effectiveness and persistence of adoptive cell therapies, and OmniCAR, a universal immune receptor platform allowing controllable T-cell activity.
YTD Price Performance: 0.0%
Average Trading Volume: 656,647
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$40.27M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.
